Keros Therapeutics Inc
KROS16.040USD
+0.420+2.69%
Close 09/18, 16:00（ET）Quotes delayed by 15 min
651.47MMarket Cap
34.70P/E TTM
More Details of Keros Therapeutics Inc Company
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. Its second product candidate, KER-012, is being developed for the treatment of pulmonary arterial hypertension, or PAH, and for the treatment of cardiovascular disorders. Its third product candidate, KER-065, is being developed for the treatment of obesity and for the treatment of neuromuscular diseases. KER-050 is designed to raise red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-B family of proteins to promote hematopoiesis.
Company Info
Ticker SymbolKROS
Company nameKeros Therapeutics Inc
IPO dateApr 08, 2020
CEODr. Jasbir Seehra, Ph.D.
Number of employees169
Security typeOrdinary Share
Fiscal year-endApr 08
Address1050 Waltham Street, Suite 302
CityLEXINGTON
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code02421
Phone16173146297
Websitehttps://www.kerostx.com/
Ticker SymbolKROS
IPO dateApr 08, 2020
CEODr. Jasbir Seehra, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Jasbir Seehra, Ph.D.
Dr. Jasbir Seehra, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
392.72K
+29.94%
Mr. Julius Knowles
Mr. Julius Knowles
Independent Director
Independent Director
6.44K
+440.81%
Mr. Jean-Jacques Bienaime ,
Mr. Jean-Jacques Bienaime ,
Independent Chairman of the Board
Independent Chairman of the Board
5.45K
+2625.00%
Dr. Carl L. Gordon, Ph.D.
Dr. Carl L. Gordon, Ph.D.
Independent Director
Independent Director
5.25K
--
Mr. Nima Farzan
Mr. Nima Farzan
Independent Director
Independent Director
5.25K
--
Mr. Tomer Kariv, J.D.
Mr. Tomer Kariv, J.D.
Independent Director
Independent Director
5.25K
--
Dr. Mary Ann Gray, Ph.D.
Dr. Mary Ann Gray, Ph.D.
Independent Director
Independent Director
5.25K
--
Mr. Justin Frantz
Mr. Justin Frantz
Head of Investor Relations
Head of Investor Relations
--
--
Mr. Keith C. Regnante
Mr. Keith C. Regnante
Chief Financial Officer
Chief Financial Officer
--
-100.00%
Dr. Alpna Hansraj Seth, Ph.D.
Dr. Alpna Hansraj Seth, Ph.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Jasbir Seehra, Ph.D.
Dr. Jasbir Seehra, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
392.72K
+29.94%
Mr. Julius Knowles
Mr. Julius Knowles
Independent Director
Independent Director
6.44K
+440.81%
Mr. Jean-Jacques Bienaime ,
Mr. Jean-Jacques Bienaime ,
Independent Chairman of the Board
Independent Chairman of the Board
5.45K
+2625.00%
Dr. Carl L. Gordon, Ph.D.
Dr. Carl L. Gordon, Ph.D.
Independent Director
Independent Director
5.25K
--
Mr. Nima Farzan
Mr. Nima Farzan
Independent Director
Independent Director
5.25K
--
Mr. Tomer Kariv, J.D.
Mr. Tomer Kariv, J.D.
Independent Director
Independent Director
5.25K
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Aug 16
Updated: Sat, Aug 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Adar1 Capital Management LLC
13.27%
Pontifax Venture Capital
11.79%
Madison Avenue Partners LP
6.63%
The Vanguard Group, Inc.
6.45%
BlackRock Institutional Trust Company, N.A.
5.88%
Other
55.98%
Shareholders
Shareholders
Proportion
Adar1 Capital Management LLC
13.27%
Pontifax Venture Capital
11.79%
Madison Avenue Partners LP
6.63%
The Vanguard Group, Inc.
6.45%
BlackRock Institutional Trust Company, N.A.
5.88%
Other
55.98%
Shareholder Types
Shareholders
Proportion
Hedge Fund
38.44%
Investment Advisor
19.91%
Investment Advisor/Hedge Fund
17.25%
Venture Capital
16.87%
Research Firm
4.47%
Private Equity
2.51%
Corporation
1.41%
Individual Investor
1.35%
Pension Fund
1.07%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
392
46.16M
114.02%
-7.54M
2025Q1
394
39.41M
98.81%
-8.43M
2024Q4
366
43.10M
106.25%
-873.01K
2024Q3
351
43.05M
114.83%
+404.61K
2024Q2
337
39.69M
109.09%
-4.15M
2024Q1
332
39.81M
110.03%
+1.08M
2023Q4
310
34.40M
109.87%
-229.62K
2023Q3
303
31.04M
104.70%
-2.97M
2023Q2
305
30.88M
104.58%
-2.59M
2023Q1
303
30.13M
102.36%
-2.18M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Adar1 Capital Management LLC
5.39M
13.27%
--
--
May 12, 2025
Pontifax Venture Capital
4.79M
11.79%
--
--
Apr 17, 2025
Madison Avenue Partners LP
2.61M
6.44%
+2.61M
--
May 14, 2025
The Vanguard Group, Inc.
2.57M
6.32%
+616.06K
+31.59%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.51M
6.18%
+40.82K
+1.65%
Mar 31, 2025
Logos Global Management LP
2.00M
4.92%
+2.00M
--
Mar 31, 2025
Nantahala Capital Management, LLC
1.51M
3.71%
+591.74K
+64.67%
Mar 31, 2025
Tang Capital Management, LLC
1.10M
2.71%
+1.10M
--
Mar 31, 2025
State Street Global Advisors (US)
1.30M
3.21%
+99.16K
+8.24%
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
